Table 5.
Psoriatic nail involvement in EOP and LOP
| Variables | Total patients (N = 160) | EOP (N = 121) | LOP (n = 39) | P |
|---|---|---|---|---|
| Nail involvement, n (%) | 87 (54.3) | 68 (56.1) | 19 (48.7) | 0.415 |
| Age at nail involvement onset, years | 34.29 ± 12.93 | 29.51 ± 10.23 | 49.85 ± 7.33 | |
| mean±SD (range) | (10–70) | (10–62) | (37–70) | < 0.01 |
| Disease duration between Ps and nail involvement, years | 7.4 ± 8.1 | 9.06 ± 8.5 | 2.1 ± 3.0 | - a, < 0.01b |
| mean±SD (range) | (4–37) | (0–37) | (4–9) | |
| Concurrent nail involvement and PsA, N (%) | 28 (17.5) | 8 (6.6) | 5 (12.8) | 0.072 a, 0.041 b |
| Active disease duration in patients with nail involvement and Rx, months | 30.63 ± 9.1 | 35 ± 48.32 | 16 ± 19.3 | 0.639 a, < 0.01 b |
| mean±SD | ||||
| Active disease duration in patients with nail involvement without Rx, months | 30.22 ± 9.8 | 34 ± 50.1 | 17 ± 18.2 | 0.027a, < 0.01 b |
| mean±SD |
EOP = early onset psoriasis; LOP = late onset psoriasis; Ps = psoriasis; PsA = psoriatic arthritis; Rx = systemic treatment; SD = standard deviation.
Pa: patients with psoriasis;
Pb: between EOP and LOP